Among these drugs, topoisomerase (doxorubicin, idarubicin, epirubicin, daunorubicin, mitoxantrone, and teniposide) and CDK (BMS-387032, JNJ-7706621, alvocidib, PHA-793887, and palbociclib) inhibitors potentially reverse ReCa signatures and inhibit the growth of CRC cell lines with transcriptional profiles similar to ReCa. Here, RAD51 is linked to colorectal carcinoma.